PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (NASDAQ:BJCT), a leading developer of needle-free drug delivery systems, today reported financial results for the second quarter ended June 30, 2007. Bioject reported revenues of $2.8 million for the quarter ended June 30, 2007, which was comparable to 2006 revenues. Product sales were $2.0 million in the 2007 period compared to $2.1 million in the comparable 2006 period. License and technology fees were $802,000 for the quarter ended June 30, 2007 compared to $638,000 in the comparable 2006 period. The Company reported an operating loss of $296,000 in the second quarter of 2007 compared to an operating loss of $2.0 million in the second quarter of 2006. Included in the 2006 operating loss was approximately $915,000 related to the write-down of assets. Net loss allocable to common shareholders for the three month period ended June 30, 2007 was $1.1 million compared to $3.0 million in the comparable 2006 period. The Company reported a $554,000 non-cash charge related to the increase in the fair value of its derivative liabilities for the second quarter of 2007. Cash, cash equivalents and marketable securities at June 30, 2007 totaled $2.1 million.
